The Federal Circuit’s July 2025 decision in Acorda Therapeutics, Inc. v. Alkermes PLC offers a clear lesson in jurisdictional strategy. Although the dispute revolved around post-expiration patent royalties, the court never reached the merits. Instead...

Markdown supported · ⌘↵ to post
No responses yet.